A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

This study is testing a combination of two drugs — zanubrutinib (a targeted drug that blocks a protein called BTK) and tislelizumab (an immunotherapy drug) — for patients with a type of blood cancer called large B-cell lymphoma that has relapsed or stopped responding after CAR-T cell therapy. **You may be eligible if...** - You are 18 or older - You have large B-cell lymphoma that came back or stopped responding within 6 weeks after CAR-T cell therapy - You have measurable disease on imaging - Your blood counts are adequate (with or without support from transfusions or growth factors) - Your liver and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your life expectancy is less than 30 days - You have previously been treated with a BTK inhibitor or a PD-1 checkpoint inhibitor (immunotherapy) - You have had a severe allergic reaction to monoclonal antibody therapy in the past Talk to your doctor to see if this trial is right for you.